Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy.
Giossi R, Consonni A, Torri Clerici V, Zito A, Rigoni E, Antozzi C, Brambilla L, Crisafulli SG, Bellino A, Frangiamore R, Bonanno S, Vanoli F, Ciusani E, Corsini E, Andreetta F, Baggi F, Tramacere I, Mantegazza R, Conte A, Bergamaschi R, Confalonieri P. Giossi R, et al. Among authors: vanoli f. Mult Scler Relat Disord. 2022 Feb;58:103415. doi: 10.1016/j.msard.2021.103415. Epub 2021 Nov 22. Mult Scler Relat Disord. 2022. PMID: 35216790 Free PMC article.
Muscle involvement in myasthenia gravis: Expanding the clinical spectrum of Myasthenia-Myositis association from a large cohort of patients.
Garibaldi M, Fionda L, Vanoli F, Leonardi L, Loreti S, Bucci E, Di Pasquale A, Morino S, Vizzaccaro E, Merlonghi G, Ceccanti M, Lucchini M, Mirabella M, Andreetta F, Pennisi EM, Petrucci A, Salvetti M, Antonini G. Garibaldi M, et al. Among authors: vanoli f. Autoimmun Rev. 2020 Apr;19(4):102498. doi: 10.1016/j.autrev.2020.102498. Epub 2020 Feb 14. Autoimmun Rev. 2020. PMID: 32062029 Review.
Complement Inhibition for the Treatment of Myasthenia Gravis.
Mantegazza R, Vanoli F, Frangiamore R, Cavalcante P. Mantegazza R, et al. Among authors: vanoli f. Immunotargets Ther. 2020 Dec 15;9:317-331. doi: 10.2147/ITT.S261414. eCollection 2020. Immunotargets Ther. 2020. PMID: 33365280 Free PMC article. Review.
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
Development and validation of the Myasthenia Gravis TeleScore (MGTS).
Pasqualin F, Guidoni SV, Albertini E, Ermani M, Frangiamore R, Vanoli F, Antozzi C, Mantegazza R, Bonifati DM. Pasqualin F, et al. Among authors: vanoli f. Neurol Sci. 2022 Jul;43(7):4503-4509. doi: 10.1007/s10072-022-05918-y. Epub 2022 Feb 28. Neurol Sci. 2022. PMID: 35226211 Free PMC article.
Ravulizumab for the treatment of myasthenia gravis.
Vanoli F, Mantegazza R. Vanoli F, et al. Expert Opin Biol Ther. 2023 Mar;23(3):235-241. doi: 10.1080/14712598.2023.2185131. Epub 2023 Mar 8. Expert Opin Biol Ther. 2023. PMID: 36852670 Clinical Trial.
59 results